In advance of the Senate Health, Education, Labor, and Pensions Committee?s meeting to be held on Friday to consider amendments to the healthcare reform bill, including several amendments related to biosimilars, Biotechnology Industry Organization?s (BIO) President and CEO Jim Greenwood reaffirmed BIO?s support for a 12-year data exclusivity period for biologics.
The introduction of two rival bills has intensified the long-simmering debate on biosimilars regulation in the US.
A new report by FTC, entitled ?Follow-on Biologic Drug Competition,? examines whether the price of biologics is likely to be reduced by competition from FOBs.
To expand coverage amidst the economic crisis, Obama will be looking hard for ways to cut healthcare costs.
The new patent regime is challenging the Indian biopharm industry to transition from generics to novel products.
How an electronics engineer led the first Indian company to carry out indigenous development of a recombinant vaccine.
